Building on venetoclax combinations is a major focus in AML. A Phase 1 trial is evaluating iadademstat, an LSD1 (lysine demethylase 1) inhibitor, combined with venetoclax and azacitidine. Laboratory research identifies a synergistic interaction between PRMT5 and LSD1 inhibitors in AML, supporting further combination studies. A Phase 2 trial is testing BCL2 inhibition with CLAG-M (cladribine, cytarabine, granulocyte colony-stimulating factor, mitoxantrone) chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → in relapsed or refractory AML.
For ALL, a Phase 2 trial is studying inotuzumab ozogamicin combined with blinatumomab with or without ponatinib in newly diagnosed Philadelphia chromosome-positive or negative ALL, potentially replacing or reducing intensive chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →.
For CML, a Phase 3 trial is evaluating rituximab with bendamustine or ibrutinib combinations versus ibrutinib alone in older CLL patients. A Phase 2 trial is studying trametinib in relapsed or refractory juvenile myelomonocytic leukemia (JMML), a rare childhood disease with few options.
Measurable residual disease (MRD) testing, which detects very small amounts of remaining leukemia after treatment, is being refined as a tool to guide therapy decisions in AML, with several studies examining its use. Artificial intelligence algorithms predicting acute leukemia subtypes from routine blood films are in development, potentially improving diagnostic speed and access.
Where the evidence stands
BCR-ABL TKIs for CML and venetoclax combinations for AML have strong Phase 2 and Phase 3 evidence. CAR-TA type of immunotherapy that reprograms a patient's own T cells to attack cancer.Click for full explanation → cell therapies for relapsed ALL have Phase 2 to Phase 3 data. Blinatumomab and inotuzumab ozogamicin in ALL rest on Phase 3 data. Combinations pushing venetoclax into earlier AML settings or with novel partners are in Phase 1 to Phase 2. LSD1 and PRMT5 inhibitor combinations show preclinical and early clinical activity. MRD-guided treatment strategies and AI diagnostic tools are earlier-phase research directions.
What this means for people affected
The leukemias have seen substantial treatment advances, particularly with targeted therapiesDrugs that block specific molecules that cancer cells need to grow.Click for full explanation → in CML, venetoclax combinations in AML, and immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation →-based approaches in ALL. For patients with specific mutationsA change in DNA sequence that can drive cancer development.Click for full explanation →, targeted agents now offer options beyond standard chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →. Molecular and genetic testing of the leukemia cells is essential to guide which treatments are most appropriate. Research is active across all leukemia subtypes, with multiple meaningful trials in Phase 2 and Phase 3 that may further expand available options.
Last updated April 2, 2026
Recent research findings
Understanding evidence levels▼
PreclinicalLab or cell studies — no human data yet.
Animal StudyResults in animals only — may not apply to humans.
Phase 1 TrialFirst-in-human safety testing in small groups.
Phase 2 TrialEarly effectiveness testing in a larger group.
Phase 3 TrialLarge controlled trial — the strongest trial evidence.
Observational StudyPatterns observed in populations — not a controlled trial.
ReviewSummary analysis of multiple existing studies.
Meta-AnalysisStatistical pooling of results from multiple studies.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: April 3, 2026
Misdiagnosis of eye lesion highlights need for accurate cancer diagnosis
Researchers reported a case of a woman in her early twenties who was initially misdiagnosed with an eye condition. Further investigation revealed a rare type of cancer called myeloid sarcoma. The patient was treated with chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → and showed complete tumour resolution.
Why it matters: This case highlights the importance of accurate diagnosis in cancer treatment.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: April 3, 2026
Global Acute Lymphoblastic Leukaemia Care Quality Improves, but Disparities Persist
Researchers analyzed global trends in acute lymphoblastic leukaemia care quality from 1990 to 2021. They found that care quality improved, but disparities in care quality persisted across regions, ages, and genders. The quality-of-care index increased from 31.35 in 1990 to 58.46 in 2021.
Why it matters: This finding highlights the need for targeted interventions to promote equitable global acute lymphoblastic leukaemia care development.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: April 2, 2026
Letermovir May Improve Outcomes for Leukemia Patients Undergoing Stem Cell Transplant
Researchers studied 88 patients who received stem cell transplants with a medication called anti-thymocyte globulin to treat leukemia or myelodysplastic syndromes. They found that patients who also received letermovir had better outcomes, including lower rates of a serious complication called CMV reactivation. However, more research is needed to confirm these findings.
Why it matters: This study may help doctors develop more effective treatments for patients undergoing stem cell transplants.
Efficacy
The 3-year overall survival rates were 85% in the letermovir group and 47% in the non-letermovir group.
The study was retrospective and involved a relatively small number of patients.
Phase 2 TrialTests early effectiveness in a larger group after phase 1 safety is established.Est. completion: January 4, 2029
Evaluating Nemtabrutinib for Hematologic Malignancies
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying the efficacy and safety of Nemtabrutinib in people with certain blood cancers. The trial is currently recruiting participants. The results of this trial are not yet available.
Why it matters: This trial aims to gather information about the effectiveness and safety of Nemtabrutinib for treating various blood cancers.
Phase 3 TrialLarge controlled trial comparing treatments. The strongest level of trial evidence.Est. completion: September 7, 2032
Nemtabrutinib vs Ibrutinib or Acalabrutinib for First-Line CLL/SLL Treatment
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying the effectiveness of nemtabrutinib compared to ibrutinib or acalabrutinib for patients with first-line chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The trial is currently recruiting participants. The results of this trial will help determine the best treatment option for these patients.
Why it matters: This trial will provide valuable information about the potential benefits and risks of nemtabrutinib for patients with CLL/SLL.
Phase 1 TrialFirst-in-human trial. Focuses on safety and dosing in small groups.Est. completion: June 30, 2027
Rapcabtagene Autoleucel and Ibrutinib for Blood Cancers
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying the safety and effectiveness of a new treatment called Rapcabtagene Autoleucel in combination with Ibrutinib for patients with certain types of blood cancers. The trial is currently active but not recruiting new participants. The results of this trial are not yet available.
Why it matters: This trial aims to provide new insights into the treatment of blood cancers such as Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, and Acute Lymphoblastic Leukemia.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: April 1, 2026
Radiation Oncologists' Accuracy in Reading MRI Scans for Prostate Cancer
Researchers studied how accurately radiation oncologists can identify prostate cancer on MRI scans. They found that the accuracy improved when the oncologists had access to a radiology report, but there was still a lot of variation in their results. An automated tool performed similarly to the oncologists' initial attempts.
Why it matters: This finding highlights the importance of radiology reports and standardized guidelines for MRI interpretation in prostate cancer treatment planning.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: April 1, 2026
Rare Cancer Treatment Success in Child with TAR Syndrome
Researchers treated a child with a rare cancer called juvenile myelomonocytic leukemia (JMML) and an underlying condition called thrombocytopenia-absent radius (TAR) syndrome. The child received a bone marrow transplant from a sibling donor and achieved full donor chimerism and hematologic remission. This is one of the first reported cases of successful treatment for JMML in a patient with TAR syndrome.
Why it matters: This finding highlights the importance of monitoring patients with TAR syndrome for potential malignant transformation and demonstrates the potential of bone marrow transplantation in rare cases.
✦ Significant findingA meaningful signal from later-stage research, or a strong phase 2 result that stands out from routine findings.Meta-AnalysisStatistical pooling of results from multiple studies.Published: April 1, 2026
New Treatment Option for Younger Acute Myeloid Leukemia Patients
Researchers analyzed data from 429 younger patients with acute myeloid leukemia who received a new treatment combination. They found that this combination led to high response ratesThe proportion of patients whose cancer shrinks or disappears after treatment.Click for full explanation → and a significant number of patients were able to proceed to a bone marrow transplant. However, more research is needed to confirm these findings.
Why it matters: This finding could provide a new treatment option for younger patients with acute myeloid leukemia and inform future research comparing this approach with standard intensive chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →.
Efficacy
The pooled complete remission rate was 66% (95% confidence interval [CI], 48%-85%), with an MRD-negative rate of 69% (95% CI, 49%-90%).
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: April 1, 2026
Triple Assessment Helps Diagnose Ductal Breast Disease
Researchers studied 100 women with nipple discharge to see how well a triple assessment (exam, imaging, and biopsy) could diagnose ductal breast disease. They found that certain factors, like age and breast lumps, were associated with a higher risk of cancer. However, more research is needed to confirm these findings.
Why it matters: This study highlights the importance of a triple assessment in evaluating ductal breast disease and identifying high-risk patients.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: April 1, 2026
Improving Access to Cancer Testing in Brazil
Researchers in Brazil studied the costs of a specific test for chronic myeloid leukemia (CML) and found that the current reimbursement fee is lower than the actual cost. They simulated scenarios to increase patient access to the test without increasing the budget impact.
Why it matters: This finding highlights the need for more effective and sustainable health policies in the CML field.
The study was conducted at a single academic reference care center in Brazil.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: April 1, 2026
Early vs Late Lung Cancer Spread in Soft-Tissue Sarcoma Patients
Researchers studied 584 patients with soft-tissue sarcoma who developed lung cancer after surgery. They found that patients who developed lung cancer early after surgery had poorer survival rates compared to those who developed it later. The exact reasons for this difference are still unclear.
Why it matters: This finding may help doctors better understand how to manage soft-tissue sarcoma and improve patient outcomes.
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
Testing a New ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia
Blinatumomab and Combination ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
